Kyowa Kirin Co., Ltd.
4151
Classificação em ações
#2444
Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused... Operating globally, Kyowa Kirin Co., Ltd. is a pharmaceutical company focused on the discovery, development, manufacturing, and marketing of innovative medical therapies. The company's core areas of expertise span oncology, nephrology, central nervous system disorders, and immunology. Its extensive product portfolio includes established medications such as ABSTRAL, a sublingual fentanyl formulation for managing breakthrough pain in cancer patients; ALLELOCK, an antihistamine for various allergic conditions; and CONIEL, a calcium channel blocker prescribed for hypertension and angina. Kyowa Kirin also provides a range of advanced biological and specialized treatments. These encompass Crysvita, a recombinant human monoclonal IgG1 antibody targeting fibroblast growth factor 23, and blood-related therapies like ESPO (human erythropoietin), NESP (an erythropoiesis stimulating agent), and GRAN (a human colony-stimulating factor). Further products in its lineup address diverse medical needs: G-LASTA/Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LEUNASE for acute lymphoblastic leukemia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for opioid-induced constipation; Nouriast/Nourianz, an adenosine receptor antagonist for Parkinson's disease; and ORKEDIA, an oral calcimimetics agent. Other significant offerings are PecFent, a nasally administered spray; POTELIGEO, a humanized monoclonal antibody targeting CC chemokine receptor 4; REGPARA for secondary hyperparathyroidism; Romiplate/Nplate, a recombinant protein promoting platelet production; and SANCUSO for managing nausea and vomiting. Beyond its current offerings, Kyowa Kirin is actively involved in pipeline development, notably through a strategic collaboration with Amgen Inc. for the joint development and commercialization of KHK4083. This Phase 3-ready, fully human anti-OX40 monoclonal antibody is being developed to treat atopic dermatitis. Established in Tokyo, Japan, in 1949, the company changed its name from Kyowa Hakko Kirin Co., Ltd. to Kyowa Kirin Co., Ltd. in June 2019. It operates as a subsidiary of Kirin Holdings Company, Limited.
Preço da ação
$15.32
Valor de mercado
$8.02B
Variação (1 dia)
0.88%
Variação (1 ano)
2.20%
País
JP
Negociar Kyowa Kirin Co., Ltd. (4151)
Categoria
Healthcare
Número de ações em circulação para Kyowa Kirin Co., Ltd. (4151)
Número de ações em circulação em June 2026: 523.56M
De acordo com os últimos relatórios financeiros e o preço das ações da Kyowa Kirin Co., Ltd., o número atual de ações em circulação é 523.56M. No final de December 2024, a empresa tinha 529.54M ações em circulação. O número de ações em circulação é geralmente afetado por desdobramentos de ações e recompra de ações.
Histórico de ações em circulação da Kyowa Kirin Co., Ltd. (4151) de 2001 a 2026
Ações em circulação no final de cada ano
| Ano | Ações em circulação | Alterar |
|---|---|---|
| 2026 (TTM) | 523.56M | 0.02% |
| 2025 | 523.45M | -1.15% |
| 2024 | 529.54M | -1.49% |
| 2023 | 537.58M | 0.03% |
| 2022 | 537.43M | 0.03% |
| 2021 | 537.27M | 0.03% |
| 2020 | 537.11M | -0.27% |
| 2019 | 538.54M | 0.00% |
| 2018 | 538.54M | -1.60% |
| 2017 | 547.29M | 0.00% |
| 2016 | 547.29M | 0.00% |
| 2015 | 547.29M | -0.01% |
| 2014 | 547.35M | -0.01% |
| 2013 | 547.39M | -0.19% |
| 2012 | 548.45M | -3.28% |
| 2011 | 567.03M | -0.47% |
| 2010 | 569.71M | -0.21% |
| 2009 | 570.94M | 43.55% |
| 2008 | 397.72M | -1.86% |
| 2007 | 405.27M | -4.17% |
| 2006 | 422.92M | -1.10% |
| 2005 | 427.64M | -0.89% |
| 2004 | 431.50M | -0.52% |
| 2003 | 433.75M | -0.11% |
| 2002 | 434.24M | 0.00% |
| 2001 | 434.24M | 0.00% |
Ações em circulação de empresas semelhantes ou concorrentes
| Empresa | Ações em circulação | Diferença | País |
|---|---|---|---|
| 892.40M | 70.45% |
US
|
|
| 2.45B | 367.49% |
US
|
|
| 1.77B | 238.26% |
US
|
|
| 0.00 | -100.00% |
US
|
|
| 796.00M | 52.04% |
CH
|
